TC
WST icon

TAP Consulting’s West Pharmaceutical WST Stock Holding History

TAP Consulting’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$3.46M Buy
10,562
+486
+5% +$153K 0.71% 39
2024
Q3 		$3.02M Buy
10,076
+2,407
+31% +$737K 0.6% 51
2024
Q2 		$2.53M Sell
7,669
-153
-2% -$54.1K 0.53% 56
2024
Q1 		$3.1M Buy
7,822
+1,325
+20% +$490K 0.68% 38
2023
Q4 		$2.29M Sell
6,497
-74
-1% -$26.2K 0.55% 46
2023
Q3 		$2.47M Sell
6,571
-1,732
-21% -$670K 0.63% 45
2023
Q2 		$3.18M Sell
8,303
-1,519
-15% -$543K 0.78% 36
2023
Q1 		$3.4M Sell
9,822
-2,010
-17% -$587K 0.83% 35
2022
Q4 		$2.78M Sell
11,832
-1,082
-8% -$256K 0.73% 40
2022
Q3 		$3.18M Buy
12,914
+744
+6% +$227K 0.85% 33
2022
Q2 		$3.68M Sell
12,170
-4,409
-27% -$1.43M 1.02% 32
2022
Q1 		$6.81M Buy
16,579
+1,535
+10% +$601K 1.78% 19
2021
Q4 		$7.06M Buy
15,044
+651
+5% +$280K 1.61% 22
2021
Q3 		$6.11M Sell
14,393
-925
-6% -$390K 1.64% 19
2021
Q2 		$5.5M Buy
15,318
+288
+2% +$95.2K 1.54% 21
2021
Q1 		$4.24M Buy
15,030
+161
+1% +$46.1K 1.31% 25
2020
Q4 		$4.21M Sell
14,869
-1,592
-10% -$447K 1.52% 20
2020
Q3 		$4.53M Sell
16,461
-2,043
-11% -$541K 1.78% 18
2020
Q2 		$4.2M Sell
18,504
-2,053
-10% -$403K 2.07% 13
2020
Q1 		$3.13M Buy
20,557
+1,069
+5% +$165K 2.11% 14
2019
Q4 		$2.93M Buy
19,488
+1,576
+9% +$229K 1.63% 19
2019
Q3 		$2.54M Buy
+17,912
New +$2.47M 1.5% 22
2019
Q1 		$1.87M Buy
+16,960
New +$1.76M 1.41% 25

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return

TAP Consulting's WST Position: Q4 2024 in Review

TAP Consulting increased its West Pharmaceutical (WST) stake by 4.8% in Q4 2024, buying an estimated $153K and bringing the position to 10,562 shares worth $3.46M. The position accounts for 0.71% of the portfolio, ranked #39.

TAP Consulting first reported a position in WST in Q1 2019 and has held it in 23 quarters since. The position peaked at $7.06M in Q4 2021. 748 funds tracked by Wall St. Rank hold WST as of Q4 2024.

  • TAP Consulting held 10,562 shares of West Pharmaceutical worth $3.46M as of Q4 2024.
  • TAP Consulting bought 486 West Pharmaceutical shares in Q4 2024, an estimated $153K.
  • West Pharmaceutical made up 0.71% of TAP Consulting's portfolio in Q4 2024, its #39 holding.
  • TAP Consulting first reported a position in West Pharmaceutical in Q1 2019 and has held it in 23 quarters since.
  • TAP Consulting's West Pharmaceutical position peaked at $7.06M in Q4 2021.
  • 748 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2024.

Based on TAP Consulting's 13F filing for Q4 2024, filed 11 Feb 2025.